Financial News

UniQure gets $450M upfront to license hemophilia B gene therapy

The Netherlands-based biotech with U.S. headquarters in Lexington has licensed its investigational gene therapy for hemophilia B to Pennsylvania's CSL Behring for an upfront payment of $450 million, with an additional $1.6 billion in milestone payments, plus royalties.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Feedback